Andrographolide Inhibits Cholangiocarcinoma Cell Migration by Down-Regulation of Claudin-1 via the p-38 Signaling Pathway

• Published in: Frontiers in pharmacology Vol. 10; p. 827
• Main Authors: Pearngam, Phorutai, Kumkate, Supeecha, Okada, Seiji, Janvilisri, Tavan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 25-07-2019
• Subjects: andrographolide; cholangiocarcinoma; claudin; metastasis; migration; natural product; Pharmacology; migration; metastasis; cholangiocarcinoma; claudin; natural product; andrographolide
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2019.00827

Andrographolide, a bioactive phytochemical from
, is emerging as a promising anticancer agent against various cancers. This study aims to investigate anticancer activities of andrographolide against cholangiocarcinoma (CCA) and to understand the underlying mechanism. The anti-proliferative activity of andrographolide was evaluated in a range of cholangiocarcinoma (CCA) cell lines including HuCCA-1, KKU-100, KKU-M213, and RMCCA-1. The anti-migration activity and the corresponding mechanism were studied in highly metastatic KKU-M213 cells. The results indicated that andrographolide significantly inhibited the proliferation of CCA cells with the 50% inhibitory growth concentration (IC
) of ∼120 µM. Andrographolide also inhibited CCA cell migration and invasion. Our further explorations demonstrated that andrographolide decreased the expression of claudin-1, a major tight junction protein, while it up-regulated the expression of Snail, a transcriptional repressor of claudin-1. Moreover, andrographolide induced the phosphorylation of Jun N-terminus kinase (JNK) and p-38 Mitogen-activated protein kinase (MAPK). Treatment with the p-38-specific inhibitor recovered the claudin-1 expression and migration ability of CCA cells. This work demonstrated the potential anticancer effects of andrographolide, indicating that andrographolide could inhibit CCA cell migration
suppression of claudin-1 through the activation of p-38 MAPK signaling pathway. This compound would be useful for development of alternative therapeutic agent for CCA.